Ovarian carcinoma patients with a tumor <i>BRCA</i> -like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trial
Philip C. Schouten(Cambridge University Hospitals NHS Foundation Trust), Rita K. Schmutzler(Weatherford College)
Cited by 0
Related Papers
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
|Nature Genetics|2010|734
BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance
|Annals of Oncology|2015|220
Gene panel testing of 5589 <i><scp>BRCA</scp>1/2</i>‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
|Cancer Medicine|2018|168
Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk
|Carcinogenesis|2007|101